On September
20, the U.S. FDA granted an accelerated approval to the antibody-drug conjugate
tisotumab vedotin for a subset of patients with recurrent or metastatic
cervical cancer. On September 29, it granted approval to the anti-EGFR antibody
cetuximab for a subset of patients with metastatic colorectal cancer. On
October 1, it approved the CAR T cell therapy brexucabtagene autoleucel for a
subset of patients with acute lymphoblastic leukemia.
Monday, October 18, 2021
FDA News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment